HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
HUTCHMED (China) LimitedNASDAQ: HCM
Net Income · Q2 FY2025 · quarter ended Jun 2025
Net income growth accelerates
Q2 FY2025 net income of $227.48M rose 1663.3% year over year, ahead of the +1212.4% change in trailing-twelve-month net income. Sequentially, it rose 0.0% from the prior quarter.
Context
- Net income amounted to 83.3% of revenue in FY2025, up 77.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 16 analysts of $68.19M (-85.1%) for the fiscal year ending Dec 2026, a slowdown from the +1114.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2025
- $227.48M+0.0% QoQ
- Last fiscal yearDec 2025
- $458.12M+1114.2% YoY
- LTMJun 2025
- $466.88M+1212.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1663.3% | -1027.8% | -2691.1 pp |
| 1 year | +1114.2% | -85.1% | -1199.3 pp |
| 3-year CAGR | — | -39.8% | — |
| 5-year CAGR | -14.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 458.12M USD
- Year-over-year change
- +1114.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 458.12M | +1114.2% |
| FY2024 | 2024-12-31 | 37.73M | -62.6% |
| FY2023 | 2023-12-31 | 100.78M | +128.0% |
| FY2022 | 2022-12-31 | (360.39M) | -115.7% |
| FY2021 | 2021-12-31 | (167.04M) | — |
Net Income vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1212.4% is the highest of 9, against a peer median of +48.6%.
- Net income amounts to 77.5% of revenue for HCM, versus a peer median of 52.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.71B EUR | +348.2% | — | 64.7% | |
| LTM Jun 2026 | $1.61B USD | +85.1% | +55.7% | 27.7% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥1.24B CNY | +212.7% | +11.7% | 221.3% |
| LTM Jun 2026 | $861.1M USD | — | -48.4% | 20.8% | |
| LTM Jul 2026 | $860.62M USD | +42.9% | +62.5% | 35.3% | |
| LTM Jun 2025 | $466.88M USD | +1212.4% | — | 77.5% | |
| LTM Jun 2026 | $460M USD | +54.4% | +9.8% | 393.2% | |
| LTM Jun 2026 | $188.21M USD | -11.4% | -26.6% | 41.9% | |
| LTM Mar 2026 | $140.06M USD | -54.4% | +24.7% | 62.2% | |
| LTM Jun 2024 | $54.07M USD | — | -15.4% | 833.1% | |
| LTM Sep 2026 | $2.81M USD | -98.7% | -12.6% | 0.2% | |
| Peer median (excluding HCM) | — | +48.6% | +9.8% | 52.0% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.04M) | (360.39M) | 100.78M | 37.73M | 458.12M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| Deferred Income Tax | (115.14M) | 0 | (102.76M) | 0 | 0 |
| Stock-Based Compensation | 41.99M | 30.59M | 36.6M | 21.61M | 15.29M |
| Change in Working Capital | 32.46M | 58.7M | 71.15M | (62.17M) | (61.02M) |
| Accounts Receivables | (35.63M) | (14.45M) | (21.34M) | (41.57M) | 28.94M |
| Inventory | (16M) | (21.21M) | 4.14M | (772K) | 9.57M |
| Accounts Payables | 9.57M | 29.94M | (32.54M) | 0 | 3.02M |
| Other Working Capital | 74.53M | 64.04M | 120.89M | (19.82M) | (102.55M) |
| Other Non-Cash Items | (3.68M) | (6.17M) | 105.28M | (9.01M) | (490.56M) |
| Operating Cash Flow | (204.22M) | (268.6M) | 219.26M | 497K | (64.83M) |
| Capital Expenditures | (16.76M) | (36.66M) | (32.61M) | (17.93M) | (14.19M) |
| Acquisitions (Net) | 159.12M | 324K | (2.99M) | 0 | 28.07K |
| Purchases of Investments | (1.37B) | (1.2B) | (1.63B) | (1.85B) | (2.75B) |
| Sales of Investments | 921.36M | 1.52B | 1.37B | 1.77B | 2.74B |
| Other Investing Activities | 930K | 16.49M | 29.5M | 1.28M | 0 |
| Investing Cash Flow | (306.32M) | 296.59M | (291.14M) | (96.06M) | (29.49M) |
| Debt Repayment | (579.77K) | (9.17M) | 61.71M | 5.61M | 6.27M |
| Common Stock Issued | 717.32M | 174K | 5.09M | 790K | 1.58M |
| Common Stock Repurchased | (27.31M) | (48.08M) | (9.07M) | (36.06M) | 0 |
| Dividends Paid | (99.74M) | (87.44M) | 0 | 0 | 0 |
| Other Financing Activities | 60.34M | 61.75M | (9.07M) | (1M) | 0 |
| Financing Cash Flow | 650.03M | (82.76M) | 48.66M | (30.67M) | 7.86M |
| Effect of Forex Changes | 2.43M | (9.49M) | (6.47M) | (3.4M) | 3.83M |
| Net Change in Cash | 141.91M | (64.26M) | (29.69M) | (129.63M) | (82.63M) |
| Free Cash Flow | (220.98M) | (305.26M) | 186.65M | (17.44M) | (79.01M) |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.